RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ARYx Therapeutics - Stock

ARYx Therapeutics ROE 2024

ARYx Therapeutics ROE

0

Ticker

ARYX

ISIN

US0433871094

In 2024, ARYx Therapeutics's return on equity (ROE) was 0, a 0% increase from the 0 ROE in the previous year.

ARYx Therapeutics Aktienanalyse

What does ARYx Therapeutics do?

ARYx Therapeutics Inc is a pharmaceutical company founded in 1997 and based in Fremont, California. The company focuses on developing innovative patented therapies for the treatment of heart diseases and other metabolic diseases. The company's business model is based on recognizing the need for new and more effective medications and focusing on the discovery and development of such therapies. ARYx Therapeutics relies on a network of experienced professionals and a rigorous research and development program. ARYx Therapeutics has several divisions, including the development of therapies for the treatment of cardiac arrhythmias, as well as metabolic diseases such as diabetes and hypercholesterolemia. In addition, the company has developed a range of products that interact with the body in innovative ways by activating or blocking specific receptors. ARYx Therapeutics' most well-known product is the antiarrhythmic drug Dronedaron. It is the first antiarrhythmic drug to receive the safety standards of the US Food and Drug Administration (FDA) and offers an effective, safe, and well-tolerated treatment for atrial fibrillation. Dronedaron is currently approved in Europe and the US and is used worldwide by doctors and hospitals as an important treatment option. Another successful product from ARYx Therapeutics is the therapeutic agent NTP-2007. It was developed to increase insulin sensitivity and improve blood sugar control in patients with type 2 diabetes. NTP-2007 utilizes a novel mechanism that enhances the effect of insulin in the body without lowering blood sugar levels. It is currently being tested in clinical trials and showing promising results. Another promising product from ARYx Therapeutics is the anesthetic Fexinidazole. It is an innovative anesthetic that works in a unique way in the body and ensures fast and effective anesthesia without causing negative side effects. Fexinidazole is currently being tested in clinical trials and could prove to be an important innovation in anesthesiology. Overall, ARYx Therapeutics has established itself as a leading company in the research and development of innovative therapies for the treatment of heart diseases and metabolic diseases. The company aims to meet the needs of patients and medical professionals and improve global healthcare by pushing the boundaries of science and technology in medicine. ARYx Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding ARYx Therapeutics's Return on Equity (ROE)

ARYx Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing ARYx Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

ARYx Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in ARYx Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about ARYx Therapeutics Stock

What is the ROE (Return on Equity) of ARYx Therapeutics this year?

The ROE of ARYx Therapeutics this year is 0 undefined.

How has the Return on Equity (ROE) of ARYx Therapeutics developed compared to the previous year?

The ROE of ARYx Therapeutics has increased by 0% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of ARYx Therapeutics?

A high ROE indicates that ARYx Therapeutics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of ARYx Therapeutics?

A low ROE can indicate that ARYx Therapeutics is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of ARYx Therapeutics affect the company?

A change in ROE (Return on Equity) of ARYx Therapeutics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of ARYx Therapeutics?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of ARYx Therapeutics?

Some factors that can influence ARYx Therapeutics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does ARYx Therapeutics pay?

Over the past 12 months, ARYx Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ARYx Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of ARYx Therapeutics?

The current dividend yield of ARYx Therapeutics is .

When does ARYx Therapeutics pay dividends?

ARYx Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ARYx Therapeutics?

ARYx Therapeutics paid dividends every year for the past 0 years.

What is the dividend of ARYx Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ARYx Therapeutics located?

ARYx Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von ARYx Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ARYx Therapeutics from 6/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/19/2024.

When did ARYx Therapeutics pay the last dividend?

The last dividend was paid out on 6/19/2024.

What was the dividend of ARYx Therapeutics in the year 2023?

In the year 2023, ARYx Therapeutics distributed 0 USD as dividends.

In which currency does ARYx Therapeutics pay out the dividend?

The dividends of ARYx Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von ARYx Therapeutics

Our stock analysis for ARYx Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ARYx Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.